{
  "eval_id": "S01",
  "eval_file": "evals/single/S01.json",
  "timestamp": "2025-09-18T17:13:27.679406+00:00",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?",
  "model_output": "Trodelvy is indicated for adults with HR-positive, HER2-negative advanced breast cancer who have received endocrine therapy and at least two prior systemic therapies, including a CDK4/6 inhibitor. The main evidence comes from the TROPiCS-02 study; please refer to the EMA SmPC for full details. If you have the SmPC or EPAR, please send it by email for my review."
}